EHA 2023 | The use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing alloSCT
Nico Gagelmann, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, talks on the results of a study evaluating the use of pacritinib in thrombocytopenic patients with myelofibrosis (MF) undergoing allogeneic stem cell transplantation (alloSCT). This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, I come from a transplant background, so, we see myelofibrosis patients in our university hospital, which is the biggest hospital for allogeneic transplantation in the world for myelofibrosis. And what we see in that setting is that thrombocytopenia for these patients it’s a real issue. It’s a real issue for safety but also for overall outcomes after transplantation. So therefore, we try to team up with a company that pacritinib it because they specifically analyzed pacritinib, a JAK inhibitor, for thrombocytopenic patients...
So, I come from a transplant background, so, we see myelofibrosis patients in our university hospital, which is the biggest hospital for allogeneic transplantation in the world for myelofibrosis. And what we see in that setting is that thrombocytopenia for these patients it’s a real issue. It’s a real issue for safety but also for overall outcomes after transplantation. So therefore, we try to team up with a company that pacritinib it because they specifically analyzed pacritinib, a JAK inhibitor, for thrombocytopenic patients. And we could show in that study that the effect of pacritinib is similar across the thrombocytopenic spectrum but also across the whole cytopenic spectrum for anemia, severe anemia, moderate anemia. So, these results can be really important to bridge people to curative therapy, but also to, like, follow-up closely over the treatment course of pacritinib without the severe toxicity of ruxolitinib with anemia, neutropenia, infection risks, etc.
Read more...
